Vildagliptin in patients with type 2 diabetes mellitus and renal impairment

被引：2
|
作者：
Groop, Per-Henrik [1 ]
Dongre, Neelesh [2 ]
Kothny, Wolfgang [2 ]
机构：
[1] Univ Helsinki, Cent Hosp, Dept Med, Div Nephrol, Helsinki, Finland
[2] Novartis Pharma AG, Basel, Switzerland
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2014年 / 106卷 / 02期
关键词：
Anti-hyperglycaemic agent; Dipeptidyl peptidase-4 inhibitor; Renal impairment; Type 2 diabetes mellitus; Vildagliptin; DPP-4; INHIBITORS;
D O I：
10.1016/j.diabres.2014.07.028
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E12 / E13
页数：2
相关论文
共 50 条
  • [1] Clinical experience with vildagliptin in patients ≥ 75 years with type 2 diabetes mellitus and moderate or severe renal impairment
    Schweizer, A.
    Dejager, S.
    [J]. DIABETOLOGIA, 2013, 56 : S370 - S371
  • [2] Efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment
    Kothny, W.
    Foley, J.
    Schweizer, A.
    Rendell, M. S.
    Lukashevich, V.
    [J]. DIABETOLOGIA, 2014, 57 : S357 - S358
  • [3] Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
    Lukashevich, Valentina
    Schweizer, Anja
    Foley, James E.
    Dickinson, Sheila
    Groop, Per-Henrik
    Kothny, Wolfgang
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2013, 9 : 21 - 28
  • [4] Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
    He, Yan-Ling
    Serra, Denise
    Wang, Yibin
    Campestrini, Joelle
    Riviere, Gilles-Jacques
    Deacon, Carolyn F.
    Holst, Jens J.
    Schwartz, Sherwyn
    Nielsen, Jace C.
    Ligueros-Saylan, Monica
    [J]. CLINICAL PHARMACOKINETICS, 2007, 46 (07) : 577 - 588
  • [5] Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus
    Yan-Ling He
    Denise Serra
    Yibin Wang
    Joelle Campestrini
    Gilles-Jacques Riviere
    Carolyn F. Deacon
    Jens J. Holst
    Sherwyn Schwartz
    Jace C. Nielsen
    Monica Ligueros-Saylan
    [J]. Clinical Pharmacokinetics, 2007, 46 : 577 - 588
  • [6] Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment
    Lukashevich, V.
    Schweizer, A.
    Foley, J.
    Shao, Q.
    Groop, P. -H.
    Kothny, W.
    [J]. DIABETOLOGIA, 2011, 54 : S332 - S333
  • [7] Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
    Schweizer, Anja
    Dejager, Sylvie
    [J]. DIABETES THERAPY, 2013, 4 (02) : 257 - 267
  • [8] Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
    Anja Schweizer
    Sylvie Dejager
    [J]. Diabetes Therapy, 2013, 4 : 257 - 267
  • [9] Vildagliptin in the treatment of type 2 diabetes mellitus
    Stamataros, George
    Schneider, Stephen H.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (12) : 1967 - 1973
  • [10] Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial
    Kothny, Wolfgang
    Lukashevich, Valentina
    Foley, James E.
    Rendell, Marc S.
    Schweizer, Anja
    [J]. DIABETOLOGIA, 2015, 58 (09) : 2020 - 2026
12345